|Bid||50.08 x 900|
|Ask||50.88 x 800|
|Day's Range||49.50 - 51.56|
|52 Week Range||45.45 - 64.43|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NUVA
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the resignation of Massimo Calafiore, executive vice president and chief commercial officer, effective August 31, 2022, to become the chief executive officer of a privately-held, orthopedics technology company. Upon Mr. Calafiore's resignation, his responsibilities will be reallocated among current members of
NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...